These findings shed new light on the therapeutic implications for glioma treatment, providing valuable insights into regulating the effect of RANGAP1 and SUMO1 throughout the course of glioma and their potential as targets for therapeutic interventions. This evidence concerns the gene SUMO1 and central nervous system cancer.